The effects of zoledronic acid on serum lipids in multiple myeloma patients

Calcified Tissue International

Volumn 82, Issue 4, 2008, Pages 258-262

  Gozzetti, Alessandro ^a   Gennari, Luigi ^a   Merlotti, Daniela ^a   Salvadori, Stefania ^a   De Paola, Vincenzo ^a   Avanzati, Annalisa ^a   Franci, Beatrice ^a   Marchini, Elena ^a   Tozzi, Monica ^a   Campagna, Maria Stella ^a   Nuti, Ranuccio ^a   Lauria, Francesco ^a   Martini, Giuseppe ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Multiple myeloma; Serum lipid; Zoledronic acid

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BONE DENSITY CONSERVATION AGENTS; CHOLESTEROL, HDL; COLLAGEN; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LIPIDS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 43049122408     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-008-9123-8     Document Type: Article

References (29)

1. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657-1663
2. Lehenkari PP, Kellinsalmi M, Napankangas JP et al (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a non-hydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255-1262
3. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
4. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643-2658
5. Russel RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanism of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int, Jan 24 [Epub ahead of print]
6. Luckman SP, Hughes De, Coxon FP et al (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res 13:581-589
7. Coxon FP, Helfrich MH, Van't Hof R et al (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15:1467-1476
8. Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18:482-492
9. Derenne S, Amiot M, Barille S et al (1999) Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048-2056
10. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:163-168
11. Fiore F, Castella B, Nuschak B et al (2007) Enhanced ability of dendritic cells to stimulate innate and adaptative immunity on short-term incubation with zoledronic acid. Blood 110:921-927
12. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E (2000) Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 15:599-604
13. Montagnani A, Gonnelli S, Cepollaro C, Campagna MS, Franci MB, Pacini S, Gennari C (2003) Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 32:15-19
14. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaun C, Faye JC, Seronie-Vivien S (2006) Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 6:60
15. Martini G, Gozzetti A, Salvadori S, Gennari L, Avanzati A, Franci B, Campagna M, Nuti R, Lauria F (2006) Zoledronic acid increases serum osteoprotegerin in early stage multiple myeloma. Haematol 91:1720-1721
16. Friedwald WT, Levy RI, Fredrickson DS (1972) Estimation of serum low density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 18:499-502
17. Nuti R, Martini G, Valenti R et al (2004) Vitamin D status and bone turnover in women with acute hip fracture. Clin Orthop Relat Res 422:208-213
18. Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVEs study). Am J Cardiol 81:582-587
19. Jones P, Davidson MH, Stein EA et al (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across dose (STELLAR trial). Am J Cardiol 92:152-160
20. Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Bioch 40:575-584
21. Ylitalo R (2002) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287-296
22. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M (2005) Bisphosphonates and atherosclerosis: why? Lupus 14:773-779
23. Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537-1538
24. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
25. Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation [letter]. N Engl J Med 356:1895-1896
26. Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
27. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gammadelta T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139:101-111
28. Aviles RJ, Martin DO, Apperson-Hansen C et al (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108:3006-3010
29. Van Wagoner DR, Nerbonne JM (2000) Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol 32:1101-1117